AVITA Medical Q2 revenue $21.7M (+18% YoY), raises FY2026 guidance to $86-89M, expects Q4 cash flow breakeven

AVITA Medical, Inc.

Q2 net revenue $21.7M (record), up 18% YoY and 13% sequentially; gross margin 81.9% (+70 bps YoY).
Net loss improved to $7.7M ($0.25 loss per share) from $9.9M ($0.38) in prior year; operating expenses down 6% YoY.
Raised FY2026 revenue guidance to $86-89M (from $80-85M), representing 20-24% YoY growth; expects Q4 2026 cash flow breakeven.
Cash, equivalents, and marketable securities $11.1M; net cash use improved to $3.2M from $9.9M in Q1.
CMS proposed 2027 Medicare payment updates for RECELL, including national physician payment and increased facility rates.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.